JP Morgan Chase’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Chase’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-414,300	Closed	-$2.71M	–	7605
2025 Q3	$2.71M	Buy	414,300 +220,400	+114%	+$1.19M	﹤0.01%	3852
2025 Q2	$836K	Buy	193,900 +184,400	+1,941%	+$905K	﹤0.01%	4494
2025 Q1	$35.5K	Buy	+9,500	New	+$81.1K	﹤0.01%	5983
2022 Q2	–	Sell	-8,620	Closed	-$953K	–	6689
2022 Q1	$953K	Buy	+8,620	New	+$1.07M	﹤0.01%	4310
2020 Q3	–	Sell	-5,407	Closed	-$1.54M	–	5629
2020 Q2	$1.54M	Sell	5,407 -5,260	-49%	-$1.56M	﹤0.01%	3270
2020 Q1	$3.07M	Buy	+10,667	New	+$2.94M	﹤0.01%	2643
2019 Q2	–	Sell	-16,667	Closed	-$1.46M	–	5886
2019 Q1	$1.46M	Buy	+16,667	New	+$1.85M	﹤0.01%	3555

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

JP Morgan Chase's KPTI Position: Q1 2026 in Review

JP Morgan Chase reduced its Karyopharm Therapeutics (KPTI) stake by 73% in Q1 2026, selling an estimated $9.68K and leaving 471 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6978.

JP Morgan Chase first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $6.85M in Q4 2019. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

JP Morgan Chase held 471 shares of Karyopharm Therapeutics worth $2.5K as of Q1 2026.
JP Morgan Chase sold 1,270 Karyopharm Therapeutics shares in Q1 2026, an estimated $9.68K.
Karyopharm Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6978 holding.
JP Morgan Chase first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
JP Morgan Chase's Karyopharm Therapeutics position peaked at $6.85M in Q4 2019.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.